Anlotinib and TQB2450 solution — Competitive Intelligence Brief

Anlotinib and TQB2450 solution (Anlotinib and TQB2450 solution) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination. Area: Oncology.

phase 3 Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination VEGFR, FGFR, RET, c-KIT (anlotinib); PD-L1 (TQB2450) Oncology Small molecule

Target snapshot

Anlotinib and TQB2450 solution (Anlotinib and TQB2450 solution) — Chinese PLA General Hospital. Anlotinib inhibits multiple receptor tyrosine kinases to block tumor angiogenesis and growth, while TQB2450 is a PD-L1 inhibitor that enhances anti-tumor immune response.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anlotinib and TQB2450 solution TARGET	Anlotinib and TQB2450 solution	Chinese PLA General Hospital	phase 3	Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination	VEGFR, FGFR, RET, c-KIT (anlotinib); PD-L1 (TQB2450)
Anlotinib hydrochloride capsule + TQB2450 injection	Anlotinib hydrochloride capsule + TQB2450 injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination	VEGFR, FGFR, PDGFR, c-Kit (anlotinib); PD-L1 (TQB2450)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-target tyrosine kinase inhibitor + PD-L1 inhibitor combination class)

1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
2. Chinese PLA General Hospital · 1 drug in this class